Alumis Misses Q2 Revenue as Costs Jump
Alumis ( NASDAQ:ALMS ) , a clinical-stage biopharmaceutical company focused on immune-mediated diseases, released its second-quarter results on August 13, 2025. The company missed consensus GAAP revenue expectations for Q2 2025 and reported sharply higher spending, mainly due to closing and ...
Alumis Completes Patient Enrollment in the Global LUMUS Phase 2b Trial of ESK-001, a Next-Generation Oral TYK2 Inhibitor for the Treatment of Systemic Lupus Erythematosus
Alumis Completes Patient Enrollment in Global LUMUS Phase 2b Trial of ESK-001, Next-Generation Oral TYK2 Inhibitor for SLE, data in ...
Alumis to Present at the Jefferies Global Healthcare Investor Conference - Alumis ( NASDAQ:ALMS )
SOUTH SAN FRANCISCO, Calif., May 29, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc. ALMS, a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that Martin Babler, President and Chief Executive Officer of Alumis, will ...
Alumis to Present at the Jefferies Global Healthcare Investor Conference
Alumis to present at Jefferies Global Healthcare Conference on June ...
Alumis Completes Enrollment of Pivotal Phase 3 ONWARD Clinical Program of Lead Candidate ESK-001, a Highly Selective, Next-Generation Oral TYK2 Inhibitor for the Treatment of Moderate-to-Severe Plaque Psoriasis
Alumis completed enrollment of Phase 3 ONWARD clinical program of ESK-001, a next-generation oral TYK2 inhibitor for moderate-to-severe plaque psoriasis ...
Alumis Completes Merger with ACELYRIN - Alumis ( NASDAQ:ALMS )
SOUTH SAN FRANCISCO, Calif., May 21, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc. ALMS, a late-stage biopharma company developing next-generation targeted therapies for patients with immune-mediated diseases, today announced that it has completed its merger with ACELYRIN, Inc.
Alumis Completes Merger with ACELYRIN
Alumis Completes Merger with ...
Alumis Stockholders Approve Merger with ACELYRIN
Alumis Stockholders Approve Merger with ...
Alumis Stockholders Approve Merger with ACELYRIN - Acelyrin ( NASDAQ:SLRN ) , Alumis ( NASDAQ:ALMS )
SOUTH SAN FRANCISCO, Calif., May 13, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc.
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
LOS ANGELES, May 13, 2025 ( GLOBE NEWSWIRE ) -- ACELYRIN, Inc. ( Nasdaq: SLRN ) , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held ...
ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases - Acelyrin ( NASDAQ:SLRN ) , Alumis ( NASDAQ:ALMS )
LOS ANGELES, May 13, 2025 ( GLOBE NEWSWIRE ) -- ACELYRIN, Inc.
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis
Special Meeting of stockholders to vote on the transaction scheduled for May ...
ACELYRIN Reiterates Benefits of Value-Maximizing Combination with Alumis - Acelyrin ( NASDAQ:SLRN ) , Alumis ( NASDAQ:ALMS )
Special Meeting of stockholders to vote on the transaction scheduled for May 13, 2025 Reminds stockholders to vote today FOR the proposed merger LOS ANGELES, May 01, 2025 ( GLOBE NEWSWIRE ) -- ACELYRIN, Inc.
Charles Schwab To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday - Comerica ( NYSE:CMA ) , Alumis ( NASDAQ:ALMS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. cut Alumis Inc. ALMS price target from $15 to $14.
Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis
Alumis and ACELYRIN Announce Amended Merger Agreement
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio. Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis ...
Alumis and ACELYRIN Announce Amended Merger Agreement - Acelyrin ( NASDAQ:SLRN ) , Alumis ( NASDAQ:ALMS )
ACELYRIN stockholders to receive increased ownership in the combined company through revised exchange ratio; Alumis and ACELYRIN stockholders to now own approximately 52% and 48%, respectively, of the combined company on a fully diluted basis
Hyatt Hotels, THOR Industries And Other Big Stocks Moving Lower On Monday - Amarin Corp ( NASDAQ:AMRN ) , Alumis ( NASDAQ:ALMS )
U.S. stocks were higher, with the Nasdaq Composite gaining over 200 points on Monday. Shares of Hyatt Hotels Corporation H fell sharply during Monday's session. Goldman Sachs analyst Lizzie Dove downgraded Hyatt Hotels from Neutral to Sell and lowered the price target from $150 to $110.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders - Akoya Biosciences ( NASDAQ:AKYA ) , OptiNose ( NASDAQ:OPTN )
NEW YORK, April 07, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Optinose, Inc.
Top 3 Health Care Stocks That May Crash In Q2 - Alumis ( NASDAQ:ALMS ) , Chimerix ( NASDAQ:CMRX )
As of April 7, 2025, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when ...
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - OPTN, SLRN, AKYA, SHYF
NEW YORK, April 04, 2025 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
Alumis and ACELYRIN File Joint Definitive Proxy Statement for Proposed Merger
Stockholders to benefit from differentiated late-stage portfolio of therapies and strong balance sheet Transaction expected to be completed in second quarter of 2025
Excelerate Energy, MediaAlpha And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - American Axle & Mfg Hldgs ( NYSE:AXL ) , Alumis ( NASDAQ:ALMS )
U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Tuesday. Shares of Excelerate Energy, Inc. EE fell sharply in today's pre-market trading. Excelerate Energy announced the pricing of upsized public offering of class A common stock.
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - SLRN, TURN, BHLB, MHLD
NEW YORK, March 27, 2025 ( GLOBE NEWSWIRE ) -- Monteverde & Associates PC ( the "M&A Class Action Firm" ) , has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report.
What's Going On With Alumis Shares Tuesday? - Alumis ( NASDAQ:ALMS )
Alumis announced that it entered into a licensing and collaboration agreement with Kaken. Alumis is licensing ESK-001, a drug aimed at treating immune dysregulation in various diseases, to Kaken for commercialization in Japan. Feel unsure about the market's next move?
Alumis and Kaken Pharmaceutical Announce Collaboration and Licensing Agreement for ESK-001 in Dermatology in Japan
Alumis and Kaken Pharmaceutical collaborate for oral next-generation TYK2 inhibitor ESK-001 in dermatology in Japan ...
Tesla To $450? Here Are 10 Top Analyst Forecasts For Thursday - Bloom Energy ( NYSE:BE ) , Alumis ( NASDAQ:ALMS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Piper Sandler cut Tesla, Inc. TSLA price target from $500 to $450.
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements - Alumis ( NASDAQ:ALMS )
- Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 -
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
- Presented Phase 2 STRIDE OLE 52-week psoriasis data at AAD 2025 demonstrating next-generation oral TYK2 inhibitor ESK-001 treatment led to robust long-term clinical responses and was well tolerated; Phase 3 ONWARD program data readout now expected 1Q 2026 -
Late-Breaking ESK-001 Phase 2 OLE Data Presented at 2025 AAD Annual Meeting Demonstrate Robust Clinical Responses Over 52-Weeks in Psoriasis
ESK-001 demonstrated robust clinical responses and was well tolerated over 52 weeks in a Phase 2 clinical trial, presented in a late-breaker at ...
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc. ( Nasdaq: ALMS ) ( "Alumis" ) and ACELYRIN, INC. ( Nasdaq: SLRN ) ( "ACELYRIN" ) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage ...
Alumis and ACELYRIN Reaffirm Strategic and Financial Rationale of Proposed Merger - Acelyrin ( NASDAQ:SLRN ) , Alumis ( NASDAQ:ALMS )
SOUTH SAN FRANCISCO, Calif. and LOS ANGELES, March 04, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc. ALMS ( "Alumis" ) and ACELYRIN, INC. SLRN ( "ACELYRIN" ) today reaffirmed their commitment to merge in an all-stock transaction, which will create a leading clinical stage biopharma company in ...
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger - Acelyrin ( NASDAQ:SLRN ) , Alumis ( NASDAQ:ALMS )
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet LOS ANGELES and SOUTH SAN FRANCISCO, Calif., March 04, 2025 ( GLOBE NEWSWIRE ) -- ACELYRIN, INC. SLRN and Alumis Inc.
ACELYRIN and Alumis Reaffirm Strategic and Financial Rationale of Proposed Merger
Combined company to benefit from differentiated late-stage portfolio of therapies and strong balance sheet ...
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders ...
ACELYRIN Determines Unsolicited Indication of Interest From Concentra Biosciences Not Reasonably Expected to Result in a Superior Proposal to Planned Alumis Merger - Acelyrin ( NASDAQ:SLRN ) , Alumis ( NASDAQ:ALMS )
All-Stock Transaction with Alumis Maximizes Long-Term Value for ACELYRIN Stockholders
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout - Alumis ( NASDAQ:ALMS )
- Late-breaking oral presentation to highlight 52-week data of ESK-001 in a Phase 2 open-label extension ( OLE ) study in adults with moderate-to-severe plaque psoriasis -
Alumis Announces Late-Breaker Psoriasis Presentation of 52-week Phase 2 OLE Data for ESK-001 at 2025 American Academy of Dermatology Annual Meeting and Accelerated Topline Phase 3 Data Readout
Alumis to Present Late-Breaker Psoriasis 52-Week Phase 2 Data Data for ESK-001 at AAD, Data from Ongoing Phase 3 in ...
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases
Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases ...
Alumis Presents Additional Phase 1 Data at ACTRIMS Forum 2025 Supporting Potential of A-005 as First-in-Class CNS Penetrant TYK2 Inhibitor for Treatment of Neuroinflammatory and Neurodegenerative Diseases - Alumis ( NASDAQ:ALMS )
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, TGI, PTMN, SLRN on Behalf of Shareholders - Portman Ridge Finance ( NASDAQ:PTMN ) , Nevro ( NYSE:NVRO )
NEW YORK, Feb. 21, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Nevro Corp.
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences
LOS ANGELES, Feb. 20, 2025 ( GLOBE NEWSWIRE ) -- ACELYRIN, INC. ( Nasdaq: SLRN ) , a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from ...
ACELYRIN Confirms Receipt of Unsolicited Indication of Interest from Concentra Biosciences - Acelyrin ( NASDAQ:SLRN ) , Alumis ( NASDAQ:ALMS )
LOS ANGELES, Feb. 20, 2025 ( GLOBE NEWSWIRE ) -- ACELYRIN, INC. SLRN, a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today confirmed receipt of an unsolicited indication of interest from Concentra ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates IPG, SLRN, PTMN, HEES on Behalf of Shareholders - Interpublic Gr of Cos ( NYSE:IPG ) , H&E Equipment Servs ( NASDAQ:HEES )
NEW YORK, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: The Interpublic Group of Companies, ...
Kuehn Law Encourages HEES, SLRN, PTMN, and IPG Investors to Contact Law Firm - Interpublic Gr of Cos ( NYSE:IPG ) , H&E Equipment Servs ( NASDAQ:HEES )
NEW YORK, Feb. 18, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Alumis ( NASDAQ:ALMS )
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc.
Alumis to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
SOUTH SAN FRANCISCO, Calif., Feb. 10, 2025 ( GLOBE NEWSWIRE ) -- Alumis Inc. ( Nasdaq: ALMS ) , a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated ...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PLYA, SLRN, NVRO, AMPS on Behalf of Shareholders - Altus Power ( NYSE:AMPS ) , Nevro ( NYSE:NVRO )
NEW YORK, Feb. 10, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Playa Hotels & Resorts N.V.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, TGI, PTMN on Behalf of Shareholders - Portman Ridge Finance ( NASDAQ:PTMN ) , Nevro ( NYSE:NVRO )
NEW YORK, Feb. 10, 2025 ( GLOBE NEWSWIRE ) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Nevro Corp.
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases
Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Company Developing and Commercializing Transformative Therapies for Immune-mediated Diseases ...
